Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Accumulated Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Accumulated Expenses for 2 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 35.77% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, up 35.77% year-over-year, with the annual reading at $4.9 million for FY2025, 35.77% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $4.9 million at Evommune, up from $2.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $4.9 million in Q4 2025, with the low at $2.9 million in Q3 2025.